|1.||Thompson, John F: 5 articles (03/2014 - 05/2007)|
|2.||Damian, Diona L: 5 articles (03/2014 - 05/2007)|
|3.||Levis, William R: 4 articles (11/2015 - 05/2006)|
|4.||Aghaei, Shahin: 3 articles (11/2008 - 01/2005)|
|5.||Bergfeld, Wilma F: 2 articles (11/2015 - 09/2014)|
|6.||Piliang, Melissa P: 2 articles (11/2015 - 09/2014)|
|7.||Suárez-Fariñas, Mayte: 2 articles (01/2015 - 10/2014)|
|8.||Correa da Rosa, Joel: 2 articles (01/2015 - 10/2014)|
|9.||Gulati, Nicholas: 2 articles (01/2015 - 10/2014)|
|10.||Krueger, James G: 2 articles (01/2015 - 10/2014)|
01/01/2010 - "Diphencyprone is a contact sensitizer used to treat dermatological conditions resulting from as altered immunological state, such as extensive alopecia areata, being partially effective and safe. "
11/01/2015 - "Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients."
09/01/2014 - "Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients."
09/01/2012 - "The safety and efficacy of diphencyprone for the treatment of alopecia areata in children."
01/01/2009 - "The efficacy of topical diphencyprone in the treatment of alopecia areata."
06/01/2002 - "This paper highlights the sometimes impressive effect of diphencyprone (DPC) sensitization on warts resistant to other treatments and is interesting in view of the fact that all the warts apparently responded, despite only a very small area being treated. "
01/01/1996 - "Diphencyprone is an effective treatment for resistant warts, especially in palmoplantar and periungual locations."
01/01/1996 - "Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study."
08/01/2006 - "Our results are compared with those previously published using diphencyprone in the treatment of palmoplantar warts."
01/01/2006 - "This paper highlights the effect of diphenylcyclopropenone (DPCP) sensitization on warts resistant to other treatments and is interesting in views of the fact that all the facial warts apparently responded. "
|3.||Melanoma (Melanoma, Malignant)
08/01/2012 - "Topical diphencyprone as an effective treatment for cutaneous metastatic melanoma."
03/01/2014 - "Topical diphencyprone (DPCP) can be used to treat in transit and cutaneously metastastatic melanoma. "
11/01/2010 - "The authors provide an update on a previously reported patient with in-transit metastatic melanoma of the scalp treated with topical diphencyprone (DPCP). "
11/01/2010 - "TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone."
05/01/2007 - "Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone."
|4.||Neoplasm Metastasis (Metastasis)
05/01/2007 - "Topical immunotherapy with diphencyprone was an inexpensive and well-tolerated treatment for extensive cutaneous melanoma metastases in our patient unsuitable for other therapies."
11/01/2015 - "Diphencyprone (DPCP) is a potent topical sensitizing agent that has been used since the late 1970s by physicians for the treatment of alopecia areata (AA), viral warts (human papillomavirus) and cutaneous metastases of melanoma. "
01/01/2005 - "Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma."
11/01/2009 - "Diphencyprone (DPCP) immunotherapy is frequently used to treat cutaneous warts and alopecia areata, and we have previously reported the use of DPCP as a single agent to successfully treat extensive, radiotherapy-resistant melanoma metastases on the scalp. "
01/01/2015 - "Diphencyprone (DPCP) is a hapten that causes delayed-type hypersensitivity (DTH) reactions in human skin, and is used as a topical therapeutic for alopecia areata, warts, and cutaneous melanoma metastases. We examined peak DTH reactions induced by DPCP (3 days post-challenge) by comprehensive gene expression and histological analysis. To better understand how these DTH reactions naturally resolve, we compared our DPCP biopsies to those from patients with psoriasis vulgaris, a chronic inflammatory disease that does not resolve. By both microarray and qRT-PCR, we found that psoriasis lesional skin has significantly lower expression of many negative immune regulators compared to peak DPCP reactions. These regulators include: interleukin-10, cytotoxic T lymphocyte-associated 4 (CTLA4), programmed cell death 1 (PD1), programmed cell death 1 ligand 1 (PDL1), programmed cell death 1 ligand 2 (PDL2), and indoleamine 2,3-dioxygenase (IDO1). Their decreased expression was confirmed at the protein level by immunohistochemistry. To more completely determine the balance of positive vs. negative immune regulators in both DPCP reactions and psoriasis, we developed one comprehensive gene list for positive regulatory (inflammatory) genes, and another for negative regulatory (immunosuppressive) genes, through Gene Ontology terms and literature review. With this approach, we found that DPCP reactions have a higher ratio of negative to positive regulatory genes (both in terms of quantity and expression levels) than psoriasis lesional skin. These data suggest that the disease chronicity that distinguishes psoriasis from transient DTH reactions may be related to absence of negative immune regulatory pathways, and induction of these is therefore of therapeutic interest. Further study of these negative regulatory mechanisms that are present in DPCP reactions, but not in psoriasis, could reveal novel players in the pathogenesis of chronic inflammation. The DPCP system used here thus provides a tractable model for primary discovery of pathways potentially involved in immune regulation in peripheral tissues. "
10/01/2014 - "Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions. "
05/01/2012 - "In a mouse model of allergy, we tested the adjuvant potential of diphenylcyclopropenone (DCP), a strong contact sensitizer, which is currently used for the treatment of a T cell-mediated hair loss disease (alopezia areata). "
07/01/1997 - "Delayed-type hypersensitivity (DTH) reactions to the experimental allergen diphenylcyclopropenone (DCP) were measured in four groups, which either trained (+) or did not train in relaxation (-) during the sensitization and/or the challenge phase. "
07/01/1997 - "Effects of relaxation on the delayed-type hypersensitivity (DTH) reaction to diphenylcyclopropenone (DCP)."
01/01/1981 - "Care should not only be taken while handling this new substance in chemical laboratories, but contact should also be avoided with the intermediate and end products in cases where a diphenylcyclopropenone contact allergy is present."
|3.||Interleukin-10 (Interleukin 10)
|4.||Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Cryotherapy (Therapy, Cold)
|4.||Phototherapy (Light Therapy)